P. Michael Conn

P. Michael Conn

Auto-generated profile, based on publicly available information

P. Michael Conn

Oregon National Primate Research Center, Oregon Health and Science University, 505 NW 185th Avenue, Beaverton, OR 97006, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2004 in Traffic
Verified
Journal Article
Open access
PDF file
AUAlfredo Ulloa‐Aguirre
Alfredo Ulloa‐Aguirre
JJJo Ann Janovick
Jo Ann Janovick
SBShaun P. Brothers
Shaun P. Brothers
PCP. Michael Conn
P. Michael Conn
The process of quality control in the endoplasmic reticulum involves a variety of mechanisms which ensure that only correctly folded proteins enter the secretory pathway. Among these are conformation‐screening mechanisms performed by molecular chaperones that assist in protein folding and prevent non‐native (or misfolded) proteins from interacting with other misfolded proteins. Chaperones play a central role in the triage of newly formed proteins prior to their entry into the secretion, retention, and degradation pathways. Despite this stringent quality control mechanism, gain‐ or loss‐of‐function mutations that affect protein folding in the endoplasmic reticulum can manifest themselves as profound effects on the health of an organism. Understanding the molecular, cellular, and energetic mechanisms of protein routing could prevent or correct the structural abnormalities associated with disease‐causing misfolded proteins. Rescue of misfolded, “trafficking‐defective”, but otherwise functional, proteins is achieved by a variety of physical, chemical, genetic, and pharmacological approaches. Pharmacologic chaperones (or “pharmacoperones”) are template molecules that may potentially arrest or reverse diseases by inducing mutant proteins to adopt native‐type‐like conformations instead of improperly folded ones. Such restructuring leads to a normal pattern of cellular localization and function. This review focuses on protein misfolding and misrouting related to various disease states and describes promising approaches to overcoming such defects. Special attention is paid to the gonadotropin‐releasing hormone receptor, since there is a great deal of information about this receptor, which has recently emerged as a particularly instructive model.

1 September 2007 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
PCP. Michael Conn
P. Michael Conn
AUAlfredo Ulloa-Aguirre
Alfredo Ulloa-Aguirre
JIJoel Ito
Joel Ito
JJJo Ann Janovick
Jo Ann Janovick
G protein-coupled receptors (GPCR) comprise the largest family of drug targets. This is not surprising as many signaling systems rely on this class of receptor to convert external and internal stimuli to intracellular responses. As is the case with other membrane proteins, GPCRs are subjected to a stringentquality control mechanism at the endoplasmic reticulum, which ensures that only correctly folded proteins enter the secretory pathway. Because of this quality control system, point mutations resulting in protein sequence variations may result in the production of misfolded and disease-causing proteins that are unable to reach their functional destinations in the cell. There is now a wealth of information demonstrating the functional rescue of misfolded mutant receptors by small nonpeptide molecules originally designed to serve as receptor antagonists; these small molecules (“pharmacoperones”) serve as molecular templates, promoting correct folding and allowing the mutants to pass the scrutiny of the cellular quality control system and be expressed at the cell surface membrane. Two of these systems are especially well characterized: the gonadotropin-releasing hormone and the vasopressin type 2 receptors, which play important roles in regulating reproduction and water homeostasis, respectively. Mutations in these receptors can lead to well defined diseases that are recognized as being caused by receptor misfolding that may potentially be amenable to treatment with pharmacoperones. This review is focused on protein misfolding and misrouting related to various disease states, with special emphasis on these two receptors, which have proved to be of value for development of drugs potentially useful in regulating GPCR trafficking in healthy and disease states.

1 September 1998 in Biology of Reproduction
Verified
Journal Article
Open access
PDF file
DSDinesh Stanislaus
Dinesh Stanislaus
SPShelly Ponder
Shelly Ponder
TJTae H. Ji
Tae H. Ji
PCP. Michael Conn
P. Michael Conn
There is evidence in several cell systems suggesting that the GnRH receptor couples to multiple G proteins. Presently there are no published studies

1 March 2010 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
PCP. Michael Conn
P. Michael Conn
AUAlfredo Ulloa-Aguirre
Alfredo Ulloa-Aguirre

1 March 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JJJo Ann Janovick
Jo Ann Janovick
PKPaul E. Knollman
Paul E. Knollman
SBShaun P. Brothers
Shaun P. Brothers
RARodrigo Ayala-Yáñez
Rodrigo Ayala-Yáñez
AAAbeer S. Aziz
Abeer S. Aziz
PCP. Michael Conn
P. Michael Conn
Despite the prevalence of G protein-coupled receptors as transducers of signals from hormones, neurotransmitters, odorants, and light, little is known about mechanisms that regulate their plasma membrane expression (PME), although misfolded receptors are recognized and retained by a cellular quality control system (QCS). Convergent evolution of the gonadotropin-releasing hormone (GnRH) receptor (GnRHR) progressively decreases inositol phosphate production in response to agonist, validated as a measure of PME of receptor. A pharmacological chaperone that optimizes folding also increases PME of human, but not of rat or mouse, GnRHR because a higher percentage of human GnRHRs are misfolded structures due to their failure to form an apparent sulfhydryl bridge, and they are retained by the QCS. Bridge formation is increased by deleting (primate-specific) Lys191. In rat or mouse GnRHR that lacks Lys191, the bridge is non-essential and receptor is efficiently routed to the plasma membrane. Addition of Lys191 alone to the rat sequence did not diminish PME, indicating that other changes are required for its effects. A strategy, based on identification of amino acids that both 1) co-evolved with the Lys191 and 2) were thermodynamically unfavorable substitutions, identified motifs in multiple domains of the human receptor that control the destabilizing influence of Lys191 on a particular Cys bridge, resulting in diminished PME. The data show a novel and underappreciated means of posttranslational control of a G protein-coupled receptor by altering its interaction with the QCS and provide a biochemical explanation of the basis of disease-causing mutations of this receptor.

1 January 2009 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
JJJo Ann Janovick
Jo Ann Janovick
GMGuadalupe Maya-Núñez
Guadalupe Maya-Núñez
AUAlfredo Ulloa-Aguirre
Alfredo Ulloa-Aguirre
IHIlpo T. Huhtaniemi
Ilpo T. Huhtaniemi
JDJames A. Dias
James A. Dias
PCP. Michael Conn
P. Michael Conn